StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)

Close on Nov 17, 2026Market cap $2.25MP/E –Yield –

BioNexus Gene Lab EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

BioNexus Gene Lab's EV/EBITDA was 688.6× on Aug 31, 2020.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2020Aug 31, 2020688.6×–

More BioNexus Gene Lab figures

See a number that looks wrong?